ST-067 is under clinical development by Simcha Therapeutics and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ST-067’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ST-067 is under development for the treatment of solid tumors including melanoma, renal cell carcinoma, triple-negative breast cancer, non-small cell lung cancer, merkel cell carcinoma, urothelial cancer, gastric cancer, cervical cancer, small-cell lung cancer, cutaneous squamous cell carcinoma, platinum resistant ovarian cancer, endometrial cancer, esophageal cancer, hepatocellular carcinoma and head and neck squamous cell carcinoma. The drug candidates is engineered interleukin-18. It is administered through subcutaneous route.
Simcha Therapeutics overview
Simcha Therapeutics, is a biotechnology company that engaged in developing biologic drugs. The company is headquartered in United States.
For a complete picture of ST-067’s drug-specific PTSR and LoA scores, buy the report here.